Equity Research firms currently have a positive stance on shares of IntelliPharmaCeutics International Inc. (NASDAQ:IPCI). The majority of analysts covering the equity have a consensus Strong Buy recommendation on the stock, yielding a score of 1.30. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $6.67 on a short term basis.
At the time of writing, the stock was trading at $2.30. This represents a change from the opening price of 0.44%. In terms of performance, year to date, the stock is 10.94%. The monthly stock performance comes in at 26.61%. For the quarter, shares are performing at 45.52%. Weekly performance analysis shows the equity at 12.05%.
In taking a look at technical levels, shares are trading 21.00% away from the 50 day simple moving average and 17.91% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -27.90% away from it’s 52- week high and 63.12% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, IntelliPharmaCeutics International Inc.’s RSI stands at 63.39. In looking at volatility levels, the shares saw weekly volatility of 9.34% and 10.01% over the past month.